Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

David McConkey

Showing results (11-20 of 71) with videos related to

Pageof 8
Sort By:
Plos One|December 29, 2012
In-frame cDNA library combined with protein complementation assay identifies ARL11-binding partnersSangkyou Lee, Ilkyun Lee, Yoonsuh Jung, et al.
Current Oncology Reports|April 7, 2004
Novel therapies for pancreatic adenocarcinomaSimona M Pino, Henry Q Xiong, David McConkey, et al.
Current Gastroenterology Reports|June 12, 2004
Novel therapies for pancreatic adenocarcinomaSimona M Pino, Henry Q Xiong, David McConkey, et al.
Molecular Cancer Therapeutics|August 8, 2006
The proteasome inhibitor NPI-0052 is a more effective inducer of apoptosis than bortezomib in lymphocytes from patients with chronic lymphocytic leukemiaStacey Ruiz, Yelena Krupnik, Michael Keating, et al.
Urologic Oncology|January 25, 2021
"Advancing bladder preservation: Biomarkers, decision-making, and therapy"David McConkey, Carolyn J M Best, Julia A Gumminger, et al.
Current Opinion in Urology|June 4, 2019
Clinical implications of molecular subtyping in bladder cancerUttam Satyal, Rahmat K Sikder, David McConkey, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 8, 2004
Induction of cell cycle arrest and apoptosis by the proteasome inhibitor PS-341 in Hodgkin disease cell lines is independent of inhibitor of nuclear factor-kappaB mutations or activation of the CD30, CD40, and RANK receptorsBei Zheng, Georgios V Georgakis, Yang Li, et al.
Expert Opinion on Biological Therapy|January 8, 2025
Integrating gene therapy into the treatment paradigm for non-muscle invasive bladder cancerAlexis R Steinmetz, Behzad Jazayeri, Morgan Pierce, et al.
The Prostate|April 25, 2003
Inhibition of proliferation of PC3 cells by the branched-chain fatty acid, 12-methyltetradecanoic acid, is associated with inhibition of 5-lipoxygenasePeiying Yang, Peter Collin, Timothy Madden, et al.
Current Opinion in Oncology|March 12, 2025
Metabolic landscape in bladder cancerSyrus Razavi, Amir Khan, De-Xue Fu, et al.
Pageof 8

Showing results (11-20 of 71) with videos related to

Sort By:
Pageof 8
Plos One|December 29, 2012
In-frame cDNA library combined with protein complementation assay identifies ARL11-binding partnersSangkyou Lee, Ilkyun Lee, Yoonsuh Jung, et al.
Current Oncology Reports|April 7, 2004
Novel therapies for pancreatic adenocarcinomaSimona M Pino, Henry Q Xiong, David McConkey, et al.
Current Gastroenterology Reports|June 12, 2004
Novel therapies for pancreatic adenocarcinomaSimona M Pino, Henry Q Xiong, David McConkey, et al.
Molecular Cancer Therapeutics|August 8, 2006
The proteasome inhibitor NPI-0052 is a more effective inducer of apoptosis than bortezomib in lymphocytes from patients with chronic lymphocytic leukemiaStacey Ruiz, Yelena Krupnik, Michael Keating, et al.
Urologic Oncology|January 25, 2021
"Advancing bladder preservation: Biomarkers, decision-making, and therapy"David McConkey, Carolyn J M Best, Julia A Gumminger, et al.
Current Opinion in Urology|June 4, 2019
Clinical implications of molecular subtyping in bladder cancerUttam Satyal, Rahmat K Sikder, David McConkey, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 8, 2004
Induction of cell cycle arrest and apoptosis by the proteasome inhibitor PS-341 in Hodgkin disease cell lines is independent of inhibitor of nuclear factor-kappaB mutations or activation of the CD30, CD40, and RANK receptorsBei Zheng, Georgios V Georgakis, Yang Li, et al.
Expert Opinion on Biological Therapy|January 8, 2025
Integrating gene therapy into the treatment paradigm for non-muscle invasive bladder cancerAlexis R Steinmetz, Behzad Jazayeri, Morgan Pierce, et al.
The Prostate|April 25, 2003
Inhibition of proliferation of PC3 cells by the branched-chain fatty acid, 12-methyltetradecanoic acid, is associated with inhibition of 5-lipoxygenasePeiying Yang, Peter Collin, Timothy Madden, et al.
Current Opinion in Oncology|March 12, 2025
Metabolic landscape in bladder cancerSyrus Razavi, Amir Khan, De-Xue Fu, et al.
Pageof 8